- FDA approves Bristol-Myers Squibb's, AstraZeneca's Farxiga
- FDA advisory committee recommends approval for Bristol-Myers Squibb's, AstraZeneca's metreleptin in generalized lipodystrophy
- Bristol-Myers Squibb sells off diabetes business
- CVS Caremark study: More education needed on genetic testing in prescribing antiplatelet drugs
- FDA approves Mekinist in combination with Tafinlar to treat patients with advanced melanoma
NEW YORK Bristol-Myers Squibb formally has begun its tender offer for biotech company ZymoGenetics, the drug maker said Friday.
Bristol-Myers Squibb announced its intent to acquire the Seattle-based company earlier this week for $885 million, or $9.75 per share.
The buyout, approved by the boards of both companies, gives Bristol-Myers Squibb ownership of Recothrom, a drug used to control bleeding during surgical procedures, and pegylated-interferon lambda, a treatment for hepatitis C that is in mid-stage clinical trials that the two companies had been developing. ZymoGenetics also had been developing IL-21, a treatment in mid-stage trials for melanoma .